The American Psychiatric Assn. has appointed a work group to identify the industry money it receives, what the funds pay for and whether to go without them. The Ad Hoc Workgroup on Adapting to Changes in Pharmaceutical Revenue was appointed last spring and is set to report to the APA’s board of trustees in October.
The move comes on the heels of intense news media and congressional scrutiny of potential conflicts of interest posed by drug- and device-makers’ support of clinical researchers, medical education programs and practicing physicians.
The whole shebang.